Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 8,141 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Clear all
Completed Phase 2 Interventional Results available

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

NCT00233454
View directory record Official record
Conditions
Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)
Interventions
Midostaurin
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 20, 2026, 11:20 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Rituximab, Lenalidomide
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
31
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Not applicable Interventional Results available

Study to Compare Laser Assisted New Attachment Procedure (LANAP) to Traditional Treatments of Chronic Periodontitis

NCT01282229
View directory record Official record
Conditions
Chronic Periodontitis
Interventions
LANAP
Device
Lead sponsor
Institute for Advanced Laser Dentistry
Other
Eligibility
25 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers

NCT00622375
View directory record Official record
Conditions
Healthy
Interventions
mesalamine
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 4 Interventional Results available

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

NCT00279201
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
138
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 2 Interventional

STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH

NCT00277875
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
ALT-711 (alagebrium chloride)
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2009 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 1 Interventional

A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

NCT00999401
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
sapacitabine and seliciclib
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Compare the Clinical Efficacy of Prototype Toothpastes.

NCT00761930
View directory record Official record
Conditions
Gingival Diseases
Interventions
Fluoride, Triclosan and fluoride, Herbal Ingredient and fluoride
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Oct 20, 2026, 11:20 AM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07460765
View directory record Official record
Conditions
Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma Mouth, Squamous Carcinoma Poorly Differentiated, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma (SCC) of the Oral Cavity, Squamous Cell Carcinoma (SCC)
Interventions
Nivo800, Nivolumab
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 11:20 AM EDT
Terminated Phase 1 Interventional

Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck

NCT00081211
View directory record Official record
Conditions
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Salivary Gland Squamous Cell Carcinoma, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Interventions
PV701
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 1 Interventional

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

NCT03048344
View directory record Official record
Conditions
Advanced Hematological Disorders
Interventions
ORH-2014
Drug
Lead sponsor
Orsenix LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
New York, New York • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 20, 2026, 11:20 AM EDT
Terminated Not applicable Interventional

Virtual Reality Technology Versus Standard Technology During Pediatric Oral Food Challenge

NCT04376242
View directory record Official record
Conditions
Food Allergy in Children, Food Allergy
Interventions
use of virtual reality, use of standard technology
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 20, 2026, 11:20 AM EDT
Suspended No phase listed Observational

Sjogren's Lung Study

NCT04843345
View directory record Official record
Conditions
Sjogren's Syndrome, Interstitial Lung Disease, Primary Pulmonary Lymphoma (Disorder), Chronic Bronchiolitis, Bronchiectasis, Lung Diseases, Cystic Lung Disease, Lymphocytic Interst. Pneumonitis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 2 Interventional

Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

NCT04093895
View directory record Official record
Conditions
Periodontitis
Interventions
PerioSept(r)
Drug
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Not applicable Interventional

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

NCT00118339
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
chemoprotection, complementary or alternative medicine procedure, management of therapy complications
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Oct 20, 2026, 11:20 AM EDT
Terminated Phase 2 Interventional Results available

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

NCT03679975
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Riluzole Oral Soluble film (ROSF) 50 mg
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Oral Androgens in Man-4: (Short Title: Oral T-4)

NCT00399165
View directory record Official record
Conditions
Contraception
Interventions
Testosterone Enanthate, Dutasteride, placebo sesame oil
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

NCT03404167
View directory record Official record
Conditions
Gonorrhoea
Interventions
AZD0914
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

NCT02039700
View directory record Official record
Conditions
Healthy
Interventions
Lesinurad 400 mg, [14C]lesinurad (100 μg per 10 mL)
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Not applicable Interventional

Oral Nutritional Supplementation in Children at Risk of Undernutrition

NCT05161000
View directory record Official record
Conditions
Undernutrition
Interventions
Oral Nutritional Supplement, Dietary counseling
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
36 Months to 107 Months
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Oneonta, Alabama • Glenwood, Arkansas • Hot Springs, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 20, 2026, 11:20 AM EDT
Active, not recruiting Phase 1 Interventional

Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

NCT05820711
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
MSC
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices

NCT03267511
View directory record Official record
Conditions
Oral Hygiene
Interventions
5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica, 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP, 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica, 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Comparing Two Different Methods of Treating Periodontal Disease

NCT00127244
View directory record Official record
Conditions
Periodontal Diseases
Interventions
Periodontal Treatment
Procedure
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Oct 20, 2026, 11:20 AM EDT
Completed Phase 1 Interventional

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

NCT01759056
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
AVX 470, Placebo
Drug
Lead sponsor
Avaxia Biologics, Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 20, 2026, 11:20 AM EDT